Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 11, 2008
Cipher Pharmaceuticals Inc. (TSX: DND) today announced that the U.S. Food and Drug Administration (FDA) has suggested an additional statistical sensitivity analysis of existing clinical data on...
-
Feb 1, 2008
Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding its appeal of the Agency's Approvable...
-
Jan 8, 2008
Cipher Pharmaceuticals Inc. (TSX: DND), an emerging specialty pharmaceutical company, today provided an update on recent developments with its products. CIP-ISOTRETINOIN In June 2007, Cipher...
-
Dec 5, 2007
Cipher Pharmaceuticals Inc. (TSX: DND) today announced that Dr. Stefan Aigner, M.D., CFA, has been appointed to its Board of Directors. Dr. Aigner has more than 20 years of experience in the...
-
Dec 4, 2007
Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has appealed the position taken by the U.S. Food and Drug Administration (FDA) in its approvable letter for CIP-TRAMADOL ER, using...